Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Thursday

Edwards Lifesciences (NYSE:EW) will likely be announcing its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect Edwards Lifesciences to announce earnings of $0.73 per share and revenue of $1.7002 billion for the quarter. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 23, 2026 at 5:00 PM ET.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $0.64 EPS. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $84.41 on Wednesday. The stock’s fifty day moving average is $87.60 and its two-hundred day moving average is $83.91. The company has a market capitalization of $48.61 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,577 shares of company stock valued at $3,855,527 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the business. Compound Planning Inc. increased its holdings in Edwards Lifesciences by 20.9% during the fourth quarter. Compound Planning Inc. now owns 3,921 shares of the medical research company’s stock valued at $334,000 after buying an additional 678 shares during the period. Corient Private Wealth LLC lifted its holdings in Edwards Lifesciences by 31.4% during the fourth quarter. Corient Private Wealth LLC now owns 108,970 shares of the medical research company’s stock worth $9,290,000 after buying an additional 26,063 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in Edwards Lifesciences by 13.4% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 251,733 shares of the medical research company’s stock worth $21,460,000 after buying an additional 29,765 shares during the period. Raymond James Financial Inc. boosted its position in Edwards Lifesciences by 5.4% during the 4th quarter. Raymond James Financial Inc. now owns 2,137,309 shares of the medical research company’s stock valued at $182,218,000 after acquiring an additional 109,097 shares in the last quarter. Finally, Beacon Pointe Advisors LLC boosted its position in Edwards Lifesciences by 3.8% during the 4th quarter. Beacon Pointe Advisors LLC now owns 19,344 shares of the medical research company’s stock valued at $1,649,000 after acquiring an additional 701 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of several research analyst reports. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, Truist Financial boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $98.95.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.